Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
CosentyxⓇ grew double digit
Sales evolution
USD m, % cc
Ex-US
US
1
GROWTH
Cosentyx E
AZ
K
KL
+12% cc
Maintaining strong momentum
"
Growing ahead of the market in rheumatology
Steady volume growth in US / EU, acceleration in other international markets
>700k patients across 5 indications treated worldwide since launch
☐
1,159
1,053
500
408
☐
China market expansion continues
645
659
Expecting double-digit growth in 2022
◉
HS submissions in 2022 (~400k potential addressable patients)
CHMP decision expected for JPSA / ERA in Q2 2022
Confirming expectations of USD 7bn+ peak sales
Q1 2021
Q1 2022
HS - Hidradenitis Suppurativa JPSA - Juvenile Psoriatic Arthritis ERA - Enthesitis related arthritis
8 Investor Relations | Q1 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation